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Since Alain Cribier performed the ﬁrst human transcatheter
aortic valve implantation (TAVI) in 2002 (1), the procedure
has evolved into a reproducible and safe technique with
>100,000 procedures performed worldwide. Early experi-
ence with new devices and techniques in Europe led to
advanced procedural techniques, and large commercial and
national registries provided real-world outcome data (2–4).
Nevertheless, despite excellent results, various studies also
demonstrated that although TAVI is a promising alternative
treatment option for patients at high risk for surgical aortic
valve replacement (SAVR), there is a group of patients who,
despite successful prosthetic valve implantation, do not
beneﬁt from the procedure. It became clear that for the
beneﬁt of these patients, as well as to improve the economic
strength and future viability of TAVI, treatment of this
futile cohort should be avoided. Therefore, major attempts
have been made to develop a clear understanding of the
characteristics of this patient group; so far, there has not
been much success.See page 901The US PARTNER (Placement of Aortic Transcatheter
Valve) trial is the ﬁrst prospective randomized trial of TAVI.
It is a noteworthy project not only because it has been jointly
designed and executed by a heart team of interventional
cardiologists and cardiac surgeons, but also because it
provides robust data to answer speciﬁc questions on the
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on the effectiveness and safety of TAVI compared with
SAVR, has been published in recent years. The outcome of
2 key publications (5,6) resulted in US Food and Drug
Administration approval for transfemoral and transapical
TAVI by using the Edwards Sapien transcatheter heart valve
(Edwards Lifesciences Corporation, Irvine, California) in
patients with symptomatic AS who are at high risk or
unsuitable for SAVR.
In this issue of the Journal, Makkar et al. (7) present
a subanalysis of cohort B, a group of patients from
PARTNER in whom the heart team of interventional
cardiologists and cardiac surgeons estimated the perioper-
ative mortality after SAVR to be 50% and who were
therefore considered unsuitable for open heart surgery. This
group is particularly interesting because it contains addi-
tional patient characteristics previously not used in TAVI
studies, which allow a speciﬁc analysis of the reasons why
certain patients were classiﬁed as inoperable for SAVR, the
gold standard treatment at the time. In addition, because
cohort B is supposed to be the highest risk group in
PARTNER, it can potentially be used to identify patients in
whom TAVI may be futile. The authors divided cohort B
into those patients who were turned down for surgery due to
surgical/technical reasons and those individuals who face
high-risk SAVR due to their general condition and
comorbidities. This grouping is useful; it has previously been
demonstrated that long-term prognosis after TAVI is
mainly affected by noncardiac comorbidities and the
patient’s general condition at the time of TAVI (2–4).
This analysis also provides new information, as there has
been a lack of understanding why patients with symptomatic
AS are denied SAVR, a fact well documented by the
European Heart Survey (8). For that reason, it is of interest
for the cardiac community, and particularly TAVI heart
teams, to understand the reasons why patients in cohort B
were classiﬁed as unsuitable for surgery by the interventional
cardiologist and surgeon. This is of even more importance,
as current risk scores for SAVR have been developed by
using only data from surgical cohorts. This resulted in
a selection bias because patients with certain risk factors
(e.g., severe liver disease, severe respiratory disease, severe
frailty) may never have been accepted for surgery and
therefore did not enter those risk model calculations. Even
the PARTNER trial provides a good example of their
weakness to classify high-risk patients for SAVR. Although
cohort B patients have a Society of Thoracic Surgeons’ score
similar to patients in cohort A (11.2% vs. 11.8%), cohort B
was classiﬁed as inoperable (estimated mortality 50%) and
cohort A only high-risk for SAVR (estimated mortality
15% but <50%). There are obviously risk factors identiﬁed
by the heart team that are not captured by currently used risk
score algorithms.
The new data presented also provide helpful information
to identify patients in whom TAVI is potentially futile.
Makkar et al. (7) demonstrate that in patients in whom
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913SAVR would be challenging due to surgical/technical
reasons such as porcelain aorta, previous radiation of the
chest, midline crossing right internal thoracic artery grafts,
or challenging access to the heart, TAVI results in excellent
outcomes. In contrast, patients who are inoperable because
of their general conditiondand in this respect, immobili-
zation and frailty as well as severe respiratory and renal
disease play an important roledface a grim future even with
TAVI. They not only have a higher mortality 2 years after
the procedure, but they also experience increased repeat
hospitalizations and reduced quality of life. Nevertheless,
these patients still do better compared with patients who
receive standard medical treatment. Those patients with
a Society of Thoracic Surgeons’ score of 15% faced the
worst prognosis, with a 1-year mortality of 43%, which rose
to 53% at 2 years, and could therefore potentially be seen as
the patient group in whom TAVI is most likely to be futile.
The excellent outcomes in patients, who for surgical/
technical reasons have been considered inoperable, make it
most likely that patients with a combination of symptomatic
AS and these surgical/technical characteristics, even if they
are younger and otherwise carry a low risk for SAVR, would
beneﬁt from TAVI treatment. Therefore, for the future,
TAVI could be considered more liberally in patients who
face technical/surgical challenges for SAVR. In these
patients, a transfemoral procedure (as in cohort B) should be
considered, but with respect to the excellent European
experience (9), appropriate patients should also be offered
transapical TAVI.
In terms of the morbidity and mortality of cohort B, it is
important to mention that in PARTNER, the ﬁrst gener-
ation of the Edwards Sapien balloon-expandable, trans-
catheter heart valve was used. This use (and the fact that for
cohort B only transfemoral access was available in this trial)
may explain why the vascular complication rates are relatively
high compared with the most recent outcomes using the
smaller, second generation of the Edwards Sapien devices
(Sapien XT, Edwards Lifesciences Corporation) presented
at this year’s EuroPCR meeting (10). Development of
treatment strategies for vascular complications and the future
availability of even-smaller devices will further reduce the
risk of vascular complications.
It is also worth mentioning that a signiﬁcant number of
patients in this trial (7), as well as in other previous TAVI
investigations (2–4), experienced paravalvular leakage.
Knowing the impact on survival even in the early years after
TAVI (11), one would expect that patient outcome willfurther improve if the incidence of paravalvular leakage could
be reduced with the next generation of transcatheter heart
valves.
These developments would further support a more liberal
indication of TAVI in younger and in general, lower-risk
patients who suffer from surgical/technical risk factors for
SAVR. How a reduction of device-related morbidity during
implantation and long-term follow-up would improve the
survival of frail patients with severe clinical comorbidities in
the long term remains to be seen.
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